Alternatively, the incomplete prevention of atherosclerotic lesions by the dual incretin receptor antagonists in diabetic mice implies that vildagliptin confers a partial anti-atherogenic effect beyond that conferred by incretins in diabetes, a disease with aggravated vascular inflammation. This evidence concerns the gene GCG and diabetes mellitus.